Skip to search formSkip to main contentSkip to account menu

ASP3026

Known as: ALK Inhibitor ASP3026, ASP-3026 
An orally available, small molecule inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK), with potential antineoplastic… 
National Institutes of Health

Related topics

Related topics

3 relations
Receptor Tyrosine Kinase Inhibition

Broader (2)

SulfonesTriazines

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Dual inhibition of IGF-IR and ALK as an effective strategy to eradicate NPM-ALK+ T-cell lymphoma
BackgroundNucleophosmin-anaplastic lymphoma kinase-expressing (NPM-ALK+) T cell lymphoma is an aggressive neoplasm. NPM-ALK, an… 
2015
2015
Characterization and Thermodynamic Stability of Polymorphs of Di(arylamino) Aryl Compound ASP3026.
ASP3026 (N-{2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}-N'-[2-(propane-2-sulfonyl)phenyl]-1,3,5-triazine-2,4… 
2014
2014
The ALK inhibitor ASP3026 eradicates NPM-ALK+ T-cell anaplastic large-cell lymphoma in vitro and in a systemic xenograft lymphoma model
NPM-ALK+ T-cell anaplastic large-cell lymphoma (ALCL) is an aggressive type of cancer. Standard treatment of NPM-ALK+ ALCL is… 
2014
2014
Safety, activity, and pharmacokinetics of an oral anaplastic lymphoma kinase (ALK) inhibitor, ASP3026, observed in a “fast follower” phase 1 trial design.
2624^ Background: The efficient early development of agents intended for selected patient populations is challenging. ASP3026 is… 
Review
2014
Review
2014
Overcoming crizotinib resistance in ALK-rearranged non-small cell lung cancer.
2013
2013
Abstract 2678: First demonstration ofin vivoPET imaging for ALK inhibitor using [11C]ASP3026, a novel brain-permeable type of ALK inhibitor.
The recent breakthrough identifying the onco-driver fusion mutant of ALK kinase and its inhibitor crizotinib commercially termed… 
2013
2013
Abstract 918: ASP3026, a selective ALK inhibitor, shows anti-tumor activity in a mouse model xenografted with NCI-H2228 intracranially.
Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DC EML4-ALK translocation has been validated as a… 
Review
2013
Review
2013
Critical Review of ALK Pathway in Solid Tumors - Present and Future
Mutations involving oncogenesis and tumor suppressor genes are well known and reported in solid malignancies. Among these fusion… 
2012
2012
Abstract 866: ASP3026, a selective ALK inhibitor, induces tumor regression in a crizotinib-refractory model and prolongs survival in an intrapleurally xenograft model
Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL EML4-ALK translocation has been validated as a… 
2011
2011
Abstract 2821: Anti-tumor activity of ASP3026, – A novel and selective ALK inhibitor -
EML4-ALK is an oncogenic fusion kinase which was first identified in non-small cell lung cancer (NSCLC), and is regarded as an… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)